Catalent breaks ground on WI expansion to support commercial biomanufacturing

By Dan Stanton contact

- Last updated on GMT

John Chiminski, Catalent’s CEO, Lieutenant Governor of Wisconsin Rebecca Kleefisch and Brian Riley, GM of Catalent Biologics in Madison break ground on new $34m facility
John Chiminski, Catalent’s CEO, Lieutenant Governor of Wisconsin Rebecca Kleefisch and Brian Riley, GM of Catalent Biologics in Madison break ground on new $34m facility
The $34m expansion at its Madison, Wisconsin site will support Phase III and commercial biologics production, says Catalent.

In August, Catalent announced it was planning to invest $34m (€31m) into its single-use biologics production site in Madison to add two 2,000L single-use bioreactor systems.

And last month the contract development and manufacturing organisation (CDMO) broke ground on the extension which, according to Mike Riley - VP and general manager of Catalent Biologics – will allow the firm to expand its offering to include commercial scale biologics.

“Upon completion of our expansion, we will be able to offer single use cGMP manufacturing batch sizes of 250 L, 500 L, 1,000 L, 2,000 L and 4,000 L,”​ he told Biopharma-Reporter.com. “This will provide a range of manufacturing options to our customers from early phase clinical to Phase III and commercial production.”

There has been continued investment at the former-GE Healthcare site ever since it began operations for Catalent in 2013​, adding a 1,000L bioreactor in 2015​ for example.

Riley said the firm has been responding to customers requiring small to medium scale capacity, but the latest expansion will “support the next phase of the site's growth into Phase III and commercial production.”

Consolidated Bio-CMO space

But according to PharmSource’s Jim Miller at a recent industry event​, over half of all commercial biologics being made by third-parties are currently contracted to Lonza and Boehringer-Ingelheim, and the rest of the bio-CMO space is “extremely consolidated.”

Therefore we asked Riley how Catalent intended to compete.

“We offer customers a compelling value proposition based on our proprietary technology platforms, flexible development and manufacturing solutions, and specialised capabilities in areas like protein characterization and bioassay services,”​ he said.

“This allows us to provide a high value-add, flexible solution to customers advancing biologic molecules through the clinic and to the market.”

He added the firm has attracted “some of the most innovative biotech companies in the world”​ and “this capacity expansion, along with continued advancement and deals around our proprietary technology platforms, will further strengthen our offering.”

Last month​, the firm was contracted by Samsung Bioepis to provide fill/finish services for its Enbrel biosimilar, recently approved in the EU​ and Canada​.

Related news

Show more

Related products

show more

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Blazar™ Platform: Rodent Virus Panel

Blazar™ Platform: Rodent Virus Panel

Viral Safety for mAb: Prevent, Detect, Remove | 16-Nov-2020 | Technical / White Paper

We have a long history of developing innovative molecular technologies for cell line characterization and lot release testing for the biopharmaceutical...

Monitoring SARS-CoV-2 interaction with ACE2

Monitoring SARS-CoV-2 interaction with ACE2

Take the Right Path Upstream with MilliporeSigma | 02-Nov-2020 | Technical / White Paper

In this technical note, we investigate the interactions between the following: The spike glycoprotein binding with ACE2, Spike glycoprotein and anti-spike...

Related suppliers

Follow us

Products

View more

Webinars